公开(公告)号：US06399637B1

公开(公告)日：2002-06-04

申请号：US09434439

申请日：1999-11-05

申请人： Darko Filić ,  Miljenko Dumić ,  Aleksandar Danilovski ,  Bo{haeck over (z)}ena Klepić ,  Ines Fistrić ,  Marina Ore{haeck over (s)}ić ,  Jasna Horvat Mikul{haeck over (c)}ić

发明人： Darko Filić ,  Miljenko Dumić ,  Aleksandar Danilovski ,  Bo{haeck over (z)}ena Klepić ,  Ines Fistrić ,  Marina Ore{haeck over (s)}ić ,  Jasna Horvat Mikul{haeck over (c)}ić

IPC分类号： A61K3147

CPC分类号： A61K31/44 ,  C07D213/53 ,  C07D213/71 ,  C07D213/74

摘要： The present invention relates to the characterization of a new crystal modification III of torasemide, to a process for the preparation thereof by the use of controlled acidifying of alkaline solutions of torasemide with inorganic or organic acids with or without addition of a crystal seed, to its use a raw material for the preparation of the crystal modification I of torasemide and of pharmaceutically acceptable salts of torasemide as well as to pharmaceutical forms containing this new crystal modification III of torasemide.

摘要翻译： 本发明涉及托拉塞米的新晶体改性III的表征，其制备方法是通过使用托拉塞米的碱性溶液与无机或有机酸（有或没有加入晶种）将其酸化至其 使用原料制备托拉塞米的晶体改性I和托拉塞米的药学上可接受的盐，以及含有托拉塞米的这种新的晶体改性III的药物形式。